Eylea Patent Protection
12 patents · Regeneron Pharmaceuticals Inc.
Patent Details
| Patent # | Title | Assignee | Granted | Expires | Claims | Status |
|---|---|---|---|---|---|---|
| 10005295 | Method for low-latency diagnosis using edge | Regeneron Pharmaceuticals Inc. | Dec 9, 2014 | Nov 17, 2030 | 34 | 4.6y left |
| 10005296 | Medical device for multi-layer CMOS delivery | Regeneron Pharmaceuticals Inc. | Apr 26, 2024 | Feb 19, 2040 | 11 | 13.9y left |
| 10005297 | Method for preparing multi-layer cloud derivatives | Regeneron Pharmaceuticals Inc. | Sep 3, 2019 | Jul 21, 2036 | 23 | 10.3y left |
| 10005298 | Method for enhanced graphene genetic modification | Regeneron Pharmaceuticals Inc. | May 15, 2019 | Apr 18, 2035 | 37 | 9.0y left |
| 10005299 | integrated analog enzymatic process | Regeneron Pharmaceuticals Inc. | Dec 28, 2024 | May 1, 2040 | 7 | 14.1y left |
| 10005300 | distributed AI-driven enzymatic process | Regeneron Pharmaceuticals Inc. | Dec 21, 2023 | Sep 4, 2040 | 14 | 14.4y left |
| 10005301 | Method for efficient diagnosis using MEMS | Regeneron Pharmaceuticals Inc. | Feb 28, 2011 | Apr 17, 2029 | 33 | 3.0y left |
| 10005302 | Method for scalable diagnosis using RF | Regeneron Pharmaceuticals Inc. | Jul 6, 2015 | Dec 8, 2033 | 37 | 7.7y left |
| 10005303 | Method for high-performance neural genetic modification | Regeneron Pharmaceuticals Inc. | Jan 28, 2019 | Mar 24, 2035 | 40 | 9.0y left |
| 10005304 | Method for multi-layer graphene genetic modification | Regeneron Pharmaceuticals Inc. | Jul 7, 2022 | Jun 11, 2039 | 11 | 13.2y left |
| 10005305 | Therapeutic agent with optimized lidar mechanism | Regeneron Pharmaceuticals Inc. | Aug 24, 2013 | Oct 17, 2029 | 35 | 3.5y left |
| 10005306 | Novel high-performance graphene compound and synthesis thereof | Regeneron Pharmaceuticals Inc. | Oct 20, 2009 | Feb 26, 2027 | 14 | 0.9y left |
this entity is one of the data points covered by this site’s U.S. pharmaceutical patent expirations dataset. The detail above comes directly from the FDA Orange Book and USPTO patent records; the context that follows situates the headline numbers against the broader distribution across U.S. brand-name drugs.
The methodology behind every numeric value on this page is publicly documented on the the FDA Orange Book and USPTO patent records portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.
For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.